Deficiency of CXCR2, but not other chemokine receptors, attenuates autoantibody-mediated arthritis in a murine model
Article first published online: 26 MAR 2010
Copyright © 2010 by the American College of Rheumatology
Arthritis & Rheumatism
Volume 62, Issue 7, pages 1921–1932, July 2010
How to Cite
Jacobs, J. P., Ortiz-Lopez, A., Campbell, J. J., Gerard, C. J., Mathis, D. and Benoist, C. (2010), Deficiency of CXCR2, but not other chemokine receptors, attenuates autoantibody-mediated arthritis in a murine model. Arthritis & Rheumatism, 62: 1921–1932. doi: 10.1002/art.27470
- Issue published online: 29 JUN 2010
- Article first published online: 26 MAR 2010
- Manuscript Accepted: 17 MAR 2010
- Manuscript Received: 18 JUN 2009
- NIH. Grant Number: R01-AR-055271
- Joslin Diabetes Center's Diabetes and Endocrinology Research Center core laboratories (funded by the NIH [National Institute of Diabetes and Digestive and Kidney Diseases])
- Fellowships from the Howard Hughes Medical Institute
- Arthritis Foundation
- Massachusetts Chapter
- Lupus Foundation of New England
Chemokines coordinate leukocyte trafficking in homeostasis and during immune responses. Prior studies of their role in arthritis have used animal models with both an initial adaptive immune response and an inflammatory effector phase. We undertook analysis of chemokines and their receptors in the effector phase of arthritis using the K/BxN mouse serum–transfer model.
A time-course microarray analysis of serum-transferred arthritis was performed, examining ankle tissue, synovial fluid, and peripheral blood leukocytes. Up-regulation of chemokines was confirmed by quantitative reverse transcriptase–polymerase chain reaction. The functional relevance of chemokine induction was assessed by transferring serum into mice deficient in CCR1–7, CCR9, CXCR2, CXCR3, CXCR5, CX3CR1, CCL2, or CCL3. Further mechanistic analysis of CXCR2 involved treatment of arthritic mice with a CXCR2 antagonist, bone marrow (BM) cell transfers with CXCR2+/− and CXCR2−/− donors and recipients, flow cytometry of synovial cells, and competition experiments measuring enrichment of CXCR2-expressing neutrophils in arthritic joints of mice with mixed CXCR2+/+ and CXCR2−/− BM cells.
Gene expression profiling revealed up-regulation of the CXCR2 ligands CXCL1, CXCL2, and CXCL5 in the joint in parallel with disease activity. CXCR2−/− mice had attenuated disease relative to CXCR2+/− littermates, as did mice receiving the CXCR2 inhibitor, while deficiency of other chemokine receptors did not affect arthritis severity. CXCR2 was required only on hematopoietic cells and was widely expressed on synovial neutrophils. CXCR2-expressing neutrophils were preferentially recruited to arthritic joints in the presence of CXCR2-deficient neutrophils.
CXCR2 (but not other chemokine receptors) is critical for the development of autoantibody-mediated arthritis, exhibiting a cell-autonomous role in neutrophil recruitment to inflamed joints.